Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

EXTERNAUTICS is an innovative biotech company established in 2007 to exploit the unique possibilities offered by the Reverse Proteomic YOMICS® Platform toward the identification and development of novel diagnostic and therapeutic markers for Oncology applications. The past ten years have seen a tremendous increase in the use of Monoclonal Antibodies for the treatment of cancer diseases. Herceptin and Erbitux are clear examples of the present trends of the cancer clinical therapy to target and kill tumor cells on the basis of specific protein markers present on the tumors. Yet, the frequency of tumor regression is still limited to a very low percentage of the patient population submitted to treatment.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

IFO - Istituti Fisioterapici Ospitalieri is a private company headquartered in Rome, Italy. The firm engages in research for cancer and provides healthcare services.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Han's United (Tianjin) Stem Cell Research Institute Co., Ltd., established on 2016-09-26, Business scope includes general items:Medical Research and Experimental Development;Human stem cell technology development and application;Cosmetics Retail;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology;Sales of Class I Medical Devices;Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Guangzhou Fuda Cancer Hospital is a tertiary specialized cancer hospital which is affiliated with the Health Department of Guangdong Province in China. It was designated a national key clinical (cancer) hospital by the National Health and Family Planning Commission in 2011. The same year, Guangzhou Fuda Cancer Hospital was honored with National Trustworthy Private Hospital by the National Institute of Hospital Administration. In 2012, China Hospital Association rated Guangzhou Fuda Cancer Hospital as China Public Confidence Model Hospital. It was accredited by JCI in 2014.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.

Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Researches on gen thereapy.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

ModiQuest specializes in the generation of monoclonal antibodies against difficult target antigens for R&D, diagnostic and therapeutic applications. Using its proprietary ModiFuse™ (hybridoma electrofusion), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest can generate very large panels of monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human, as well as transgenic animals harboring the human immunoglobulin (antibody) gene repertoire, against virtually any target. Besides antibody lead generation, ModiQuest also provides extensive antibody development and optimization procedures, such as affinity maturation, humanization, stable cell line generation and antibody production in transient and stable mammalian cell systems.

Link Genomics, Inc is a private company headquartered in Tokyo, Japan. The firm develops anti-cancer drug technologies based on genome and proteome analysis. It was founded in 2001. Shinichiro Niwa is currently the CEO of the company.

MicroDiag Biomedicine focuses on the treatment of cancer, Alzheimer's, acute infectious diseases, and other major diseases. The company was founded in 2008 and is headquartered in Suzhou, Jiangsu, China.